Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELPIS human umbilical cord mesenchymal stem cells injection
- Development stage
- Unknown
- Lead developer
- 华夏源
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ELPIS human umbilical cord mesenchymal stem cells injection is an allogeneic, off-the-shelf stem cell therapy developed by Huaxia Yuan Cell Engineering Group (also known as Huaxiayuan (Shanghai) Biotechnology). The therapy utilizes human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) which possess high proliferative capacity, low immunogenicity, and potent immunomodulatory and regenerative properties. ELPIS is designed to treat various autoimmune, inflammatory, and degenerative conditions. Its mechanism of action involves regulating the Th17/Treg immune balance, suppressing inflammatory cytokines, and secreting paracrine factors (such as VEGF, bFGF, HGF, and IL-6) that promote tissue repair, angiogenesis, and inhibit fibrosis. The drug is being evaluated in clinical trials in China for several indications, including moderate-to-severe chronic plaque psoriasis, lupus nephritis, acute-on-chronic (subacute) liver failure, moderate-to-severe intrauterine adhesions (uterine synechiae), and active inflammatory bowel disease.
- Other names
- ELPIS human umbilical cord mesenchymal stem cell injectionELPIS人脐带间充质干细胞注射液ELPIS hUC-MSC
Beyond the preview
Go deeper on ELPIS human umbilical cord mesenchymal stem cells injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELPIS human umbilical cord mesenchymal stem cells injection.